Osteosarcoma (OS) is a primary malignant bone tumor with a high propensity for metastasis, particularly in adolescents and young adults. Despite advances in cancer therapy, the current standard of care for OS has remained largely unchanged since the 1980s, resulting in suboptimal survival rates, particularly for patients with metastatic disease.